Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Gilead sciences, inc. save search
Global Acute Repetitive Seizures Market to Showcase Promising Growth says Brandessence Market Research
Published: 2023-05-15 (Crawled : 10:00) - prnewswire.com
UCBJY | $63.676 -4.38% 7.2K
|
Manufacturing
|
| O: 1.79%
H: 0.18%
C: -0.06%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.01%
H: 0.14%
C: -0.78%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.22%
H: 0.14%
C: -0.2%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.35%
H: 0.83%
C: -0.73%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.17%
H: 1.07%
C: 0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.13%
H: 0.42%
C: 0.4%
research global growth market
Global API and Pharmaceutical Excipients Market Report 2022-2029 Featuring Catalent, Divis Labs, Euroapi Lonza, Pfizer, Samsung Biologics, Teva, Thermo Fisher Scientific, Wuxi Apptec, & Wuxi Biologics
Published: 2023-03-06 (Crawled : 20:00) - prnewswire.com
CMXHF | $172.54 -19.21% 50
|
n/a
|
| O: -0.86%
H: 0.33%
C: 0.33%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: -0.02%
H: 0.54%
C: -1.7%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.57%
H: 1.62%
C: 1.62%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.39%
C: -2.14%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -1.21%
H: 0.43%
C: -3.58%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.83%
H: 0.06%
C: -1.2%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.76%
H: 1.91%
C: 1.26%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.32%
H: 0.17%
C: -1.53%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.01%
H: 0.42%
C: -2.62%
CTLT | $55.48 -0.57% -0.4% 1.6M
|
Health Technology
|
| O: 0.11%
H: 0.53%
C: -5.05%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.41%
H: 0.04%
C: -1.71%
ALB | $112.15 0.31% -0.13% 2M
|
Process Industries
|
| O: -0.95%
H: 1.02%
C: -2.19%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.19%
H: 0.06%
C: -1.7%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: -1.25%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: -2.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.9%
H: 0.28%
C: -1.3%
global report market
Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others
Published: 2021-06-04 (Crawled : 16:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: -0.06%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: 1.07%
H: 3.01%
C: 0.45%
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -1.07%
H: 2.53%
C: 0.84%
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 2.46%
H: 8.41%
C: 6.91%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 1.53%
H: 9.81%
C: 6.61%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 0.0%
H: 2.74%
C: 0.68%
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 1.78%
H: 6.25%
C: 3.0%
therapy car-t iot t-cell
Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
Published: 2022-08-12 (Crawled : 14:20) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.61%
H: 0.9%
C: 0.73%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.16%
H: 1.53%
C: 1.33%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 0.61%
H: 23.78%
C: 22.56%
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -1.7%
H: 12.62%
C: 8.91%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.42%
H: 0.45%
C: 0.4%
CABA | $13.31 -4.72% -4.96% 1.2M
|
Health Technology
|
| O: 2.76%
H: 4.7%
C: 2.68%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 3.58%
H: 1.99%
C: -1.41%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.07%
H: 0.54%
C: -0.05%
global report funding therapy market
Hepatitis B and C diagnostics market size to increase by USD 2.05 billion, Technavio
Published: 2024-03-27 (Crawled : 14:30) - prnewswire.com
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
|
| O: 0.56%
H: 0.16%
C: -0.43%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 0.4%
H: 2.3%
C: 0.9%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.7%
H: 0.19%
C: 0.12%
hepatitis diagnostics market
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $69.14 1.33% 0.0% 190K
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.47 -7.17% -7.73% 870K
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
Published: 2021-11-15 (Crawled : 16:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.27%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.34%
H: 1.74%
C: -0.4%
treatment europe ulcerative colitis
JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
jyseleca treatment license ulcerative colitis
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Published: 2022-11-11 (Crawled : 12:20) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.44%
H: 0.7%
C: 0.5%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.55%
H: 1.8%
C: 1.41%
jyseleca chmp review
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-01 (Crawled : 22:00) - biospace.com/
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
|
| O: 0.97%
H: 1.48%
C: 1.19%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.16%
H: 0.01%
C: -0.47%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.14%
H: 2.85%
C: 2.65%
financial results ces results
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Published: 2021-10-04 (Crawled : 06:00) - globenewswire.com
GLPGF | News | $35.5157 71.75% 4.8K
|
Health Technology
|
| O: -4.52%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.09%
H: 1.21%
C: -0.94%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -1.82%
H: 0.04%
C: -1.29%
disease phase 3 enroll
Jyseleca® approved in Japan for ulcerative colitis
Published: 2022-03-28 (Crawled : 08:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.07%
H: 0.7%
C: 0.39%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 1.83%
H: 1.42%
C: -1.11%
jyseleca ulcerative colitis
Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Published: 2023-02-08 (Crawled : 00:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: -0.35%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -8.03%
H: 0.95%
C: 0.75%
disease topline trial results
Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
Published: 2023-02-27 (Crawled : 01:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.1%
H: 0.15%
C: -0.35%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -2.12%
H: 2.19%
C: 1.5%
extension study ulcerative colitis
Galapagos announces full year 2022 results and outlook for 2023
Published: 2023-02-23 (Crawled : 22:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.33%
H: 0.04%
C: -1.96%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -7.42%
H: 5.64%
C: 4.06%
year
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
Published: 2023-06-15 (Crawled : 20:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.46%
H: 0.31%
C: -0.15%
LIVN | $52.31 -0.85% -0.86% 430K
|
Health Technology
|
| O: 1.2%
H: 1.92%
C: 1.59%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.32%
H: 0.35%
C: -0.49%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.35%
H: 1.23%
C: -0.49%
financial
Galapagos announces first quarter 2023 financial results
Published: 2023-05-04 (Crawled : 20:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.29%
H: 1.37%
C: 1.27%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 2.86%
H: 3.14%
C: 2.95%
financial results
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
Published: 2023-05-22 (Crawled : 20:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.03%
H: 1.22%
C: -0.03%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: 0.31%
H: 1.23%
C: -0.45%
immunology
Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
Published: 2023-04-26 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -1.58%
H: 0.21%
C: -0.59%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.08%
H: 2.5%
C: 2.11%
active program
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Published: 2023-10-30 (Crawled : 20:00) - globenewswire.com
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 1.44%
C: 1.22%
GLPG | News | $29.095 0.64% 0.64% 87K
|
Health Technology
|
| O: -0.27%
H: 2.29%
C: 2.04%
jyseleca transfer business
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.